This randomized trial compares the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic venous thromboembolism in patients with active cancer.
This article analyzes diagnostic testing methods for a patient with suspected pulmonary embolism.
This randomized trial compared the efficacy and safety of 6 vs 24 months of warfarin treatment for preventing recurrent thromboembolism in patients with a first episode of symptomatic unprovoked pulmonary embolism.
This randomized trial compares the effects of a retrievable inferior vena cava filter plus anticoagulation with anticoagulation alone for prevention of recurrent pulmonary embolism in patients hospitalized with venous thromboembolism.
This prospective economic evaluation reports that use of LMW heparin for venous thromboembolism prophylaxis in critically ill patients was more effective than unfractionated heparin, with similar or lower costs.
Chatterjee and coauthors performed a meta-analysis to determine benefits and risks associated with thrombolytic therapy vs anticoagulation in acute pulmonary embolism, including the subset of hemodynamically stable patients with right ventricular dysfunction. In an Editorial, Beckman discusses how to assess the net clinical benefit of thrombolysis for patients with pulmonary embolism.
Righini and coauthors prospectively validate among 3346 patients in Belgium, France, the Netherlands, and Switzerland whether an age-adjusted D-dimer cut-off, defined as age × 10 in patients aged 50 years or older, can safely increase the diagnostic yield of D-dimer in elderly patients with suspected pulmonary embolism.